Omeros Management
Management criteria checks 3/4
Omeros' CEO is Greg Demopulos, appointed in Jun 1994, has a tenure of 29.83 years. total yearly compensation is $3.73M, comprised of 23.7% salary and 76.3% bonuses, including company stock and options. directly owns 9.84% of the company’s shares, worth $17.45M. The average tenure of the management team and the board of directors is 7.7 years and 17.3 years respectively.
Key information
Greg Demopulos
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 23.7% |
| CEO tenure | 29.8yrs |
| CEO ownership | 9.8% |
| Management average tenure | 7.7yrs |
| Board average tenure | 17.3yrs |
Recent management updates
Recent updates
Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Omeros posts preliminary results from early-stage OMS906 trial
Jun 09Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?
Jun 05Omeros posts preliminary results from COVID-19 patients treated with narsoplimab
May 28CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
May 04What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?
Mar 03Update: Omeros (NASDAQ:OMER) Stock Gained 73% In The Last Five Years
Jan 27Omeros: A Ripening Fruit Ready To Pick
Dec 09Omeros: Ending 2020 On Some High Notes
Dec 05Rainbows and Unicorns: Omeros Corporation (NASDAQ:OMER) Analysts Just Became A Lot More Optimistic
Dec 05
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$175m |
| Sep 30 2023 | n/a | n/a | -US$182m |
| Jun 30 2023 | n/a | n/a | -US$185m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$882k | -US$182m |
| Sep 30 2022 | n/a | n/a | -US$183m |
| Jun 30 2022 | n/a | n/a | -US$173m |
| Mar 31 2022 | n/a | n/a | -US$181m |
| Dec 31 2021 | US$7m | US$848k | -US$192m |
| Sep 30 2021 | n/a | n/a | -US$217m |
| Jun 30 2021 | n/a | n/a | -US$211m |
| Mar 31 2021 | n/a | n/a | -US$194m |
| Dec 31 2020 | US$6m | US$817k | -US$173m |
| Sep 30 2020 | n/a | n/a | -US$130m |
| Jun 30 2020 | n/a | n/a | -US$108m |
| Mar 31 2020 | n/a | n/a | -US$89m |
| Dec 31 2019 | US$5m | US$794k | -US$147m |
| Sep 30 2019 | n/a | n/a | -US$79m |
| Jun 30 2019 | n/a | n/a | -US$102m |
| Mar 31 2019 | n/a | n/a | -US$121m |
| Dec 31 2018 | US$5m | US$770k | -US$127m |
| Sep 30 2018 | n/a | n/a | -US$120m |
| Jun 30 2018 | n/a | n/a | -US$88m |
| Mar 31 2018 | n/a | n/a | -US$68m |
| Dec 31 2017 | US$5m | US$748k | -US$53m |
Compensation vs Market: Greg's total compensation ($USD3.73M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
CEO
Greg Demopulos (64 yo)
29.8yrs
Tenure
US$3,728,686
Compensation
Dr. Gregory A. Demopulos, M.D., also known as Greg, founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 29.8yrs | US$3.73m | 9.84% $ 17.5m | |
| Chief Accounting Officer | 10.6yrs | US$771.51k | 0.024% $ 42.8k | |
| VP, General Counsel & Corporate Secretary | 4.8yrs | US$741.27k | 0.00035% $ 620.6 | |
| Co-Founder | no data | no data | no data | |
| Chief Scientific Officer & VP of Science | 12.3yrs | no data | no data | |
| Vice President of Human Resources | 3.8yrs | no data | no data | |
| Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | 11.5yrs | no data | no data | |
| VP & Chief Commercial Officer | 3.3yrs | no data | no data | |
| VP & Chief Medical Officer | less than a year | no data | no data |
7.7yrs
Average Tenure
62yo
Average Age
Experienced Management: OMER's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 29.8yrs | US$3.73m | 9.84% $ 17.5m | |
| Lead Independent Director | 29.3yrs | US$113.22k | 0.061% $ 107.3k | |
| Independent Director | 23.1yrs | US$88.60k | 0.13% $ 227.6k | |
| Independent Director | 11.6yrs | US$90.72k | 0.021% $ 37.9k | |
| Director | 29.3yrs | US$78.72k | 0.64% $ 1.1m | |
| Independent Director | 5.2yrs | US$82.60k | 0.017% $ 30.6k | |
| Independent Director | 8.8yrs | US$88.10k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data |
17.3yrs
Average Tenure
69yo
Average Age
Experienced Board: OMER's board of directors are seasoned and experienced ( 17.3 years average tenure).